Biopharmaceutical company ImaRx Therapeutics of Tucson, AZ, reported revenue gains for the third quarter of 2007.
For the period (end-September 30), revenue was $2.3 million, up from $200,000 in 2006. Revenue for the nine-month period was $5.7 million, compared to $600,000 the previous year.
ImaRx attributed the revenue growth to sales of Abbokinase, its therapy for the treatment of acute massive pulmonary embolism, which accounted for $2.3 million in revenue in the third quarter.
The company's net loss for the period was $2.7 million, compared to $4 million in the third quarter of 2006.
By AuntMinnie.com staff writers
November 9, 2007
Related Reading
ImaRx posts Q2 revenue growth, lower net loss, August 31, 2007
ImaRx wins NIH study grant, August 23, 2007
ImaRx prices IPO, shares edge lower, July 27, 2007
Bracco, ImaRx sign licensing pact, July 4, 2007
ImaRx files S-1 for IPO, May 5, 2007
Unger steps down at ImaRx, October 24, 2006
Copyright © 2007 AuntMinnie.com
